Reviewing Guardant Health (NASDAQ:GH) & InfuSystem (NYSE:INFU)

Guardant Health (NASDAQ:GH) and InfuSystem (NYSE:INFU) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Guardant Health and InfuSystem, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	1	0	24	1	2.96
InfuSystem	0	1	2	0	2.67

Guardant Health currently has a consensus target price of $188.12, indicating a potential upside of 6.70%. InfuSystem has a consensus target price of $17.50, indicating a potential upside of 37.80%. Given InfuSystem’s higher probable upside, analysts plainly believe InfuSystem is more favorable than Guardant Health.

Profitability

This table compares Guardant Health and InfuSystem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guardant Health	-38.33%	N/A	-25.40%
InfuSystem	1.12%	2.78%	1.41%

Valuation & Earnings

This table compares Guardant Health and InfuSystem”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$1.18 billion	20.00	-$416.28 million	($3.49)	-50.52
InfuSystem	$143.34 million	1.79	$870,000.00	$0.41	30.98

InfuSystem has lower revenue, but higher earnings than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Guardant Health has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Institutional & Insider Ownership

92.6% of Guardant Health shares are owned by institutional investors. Comparatively, 71.1% of InfuSystem shares are owned by institutional investors. 5.6% of Guardant Health shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

InfuSystem beats Guardant Health on 8 of the 15 factors compared between the two stocks.

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.